Genital infectionswith human papillomavirus(HPV) are increasingly recognized as a significant source of human disease; HPV is now implicated in up to 90% of cervicalcarcinomas.Neutralizing antibodies against papillomaviruses recognize conformational epitopes formed when viral capsid proteins assemble into virions or virus-like particles. Immunization with plasmid DNA encoding the major viral capsid protein L1 was studied as a means of inducing neutralizing antibodies and protection against virus challenge. In a cottontail rabbit papillomavirus (CRPV) model, immunization with plasmid DNA encoding L1 elicited conformationally specific neutralizing antibodies and provided immunity against papilloma formation upon challenge with CRPV. Immunization with DNA encoding the capsid protein may provide a means of protecting humans against HPV and would simplifythe production of multivalent vaccines by combining plasmids that encode the viral capsid proteins of different strains. This may be of importance given the multiplicityof HPV types capable of causing disease.
Genital infection with human papillomavirus (HPV) is increasingly recognized as a source of sexually transmitted disease in the United States [1], Infection with HPV may cause genital condylomas and cervical neoplasia and may be associated with as many as 90% of cervical carcinomas [2] . There are at least 76 types of HPV, and -40 infect the human reproductive tract [3] . Types 16, 18, 31, 33, 35, 45 , and 56 are commonly found in premalignant dysplasias and cervical carcinomas and are thought to be etiologic agents for cancer, whereas types 6, 11, 42, 43, and 44 are the most common causes of genital condylomas [3] . Both the carcinoma-and condyloma-associated types may be found in cervical intraepithelial neoplasia [3] .
Efforts to produce a vaccine against HPV have centered on the major capsid protein, L1, the primary constituent of the surface of the mature virion [1] . The association of L1 monomers into viral capsids, during natural infection or by recombinant expression of L1, forms the epitopes that are recognized by neutralizing antibodies [4] [5] [6] . Immunization with HPV-ll induces neutralizing antibodies that recognize recombinant HPV-11 L1 only when it is assembled into virus-like particles (VLPs) [5] . Thus, the need for properly assembled capsids to elicit neutralizing antibodies and for the combination of multiple types in a single vaccine are potential challenges to a recombinant protein approach to immunization against HPV.
Immunization with polynucleotide vaccines (nonreplicating DNA plasmids encoding viral antigens) might prove advantageous if properly assembled L1 protein could be presented to the immune system. In animal models of influenza, DNA vaccines have facilitated the delivery of combinations of protein antigens and provided a means by which cell-mediated immunity, such as cytotoxic T lymphocytes (CTL), may be induced [7, 8] .
Papillomavirus capsid proteins contain nuclear localization signals and are targeted to the nucleus rather than to the cell surface; hence, the assembly of papillomavirus virions occurs in the nucleus of infected epithelial cells [9] . Thus, it was not obvious that the injection of L1 DNA would provide properly folded and assembled protein or that the protein would be available for immune recognition.
In previous studies, intramuscular immunization of mice, ferrets, and nonhuman primates with DNA coding for the hemagglutinin (HA) of influenza virus elicited hemagglutinationinhibiting (HI) and neutralizing antibodies [7, 8] , while immunization of mice with DNA coding for hepatitis B surface antigen induced antibodies that recognized 22-nm subvirion particles [10] . The epitopes of these proteins that are recognized by antibodies are conformational in nature, and the ability of DNA immunization to elicit such antibodies indicates that the appropriate conformation of the encoded protein was presented to the immune system. However, both of these antigens are integral membrane proteins that are targeted for expression on the surface of infected cells [11] .
Proteins such as HPV L1 that are destined for transport to the nucleus may undergo very different posttranslational processing and are not necessarily secreted nor might they be expressed at the cell surface. Thus, we investigated whether immunization with DNA encoding the L1 protein of a papillomavirus might be capable of eliciting neutralizing antibodies and protecting against the formation of papillomas. This would indicate a potential utility for the prevention of clinically apparent HPV infection. We used cottontail rabbit papillomavirus (CRPV) as a laboratory model to evaluate the ability of Ll DNA to elicit neutralizing antibodies and protective immunity. Infection with CRPV causes dermal papillomas in both cottontail rabbits and New Zealand White rabbits. Infected rabbits develop virusneutralizing antibodies and are resistant to subsequent challenges with CRPV, although existing papillomas in the rabbits may not regress [12, 13] . As with HPV, CRPV capsids are capable of eliciting neutralizing antibody responses, whereas denatured capsid proteins are not [5, 14] . Immunization with recombinant-derived CRPV capsids also protects rabbits against developing papillomas upon challenge with infectious CRPV [6, 12, 15, 16] .
In the rabbit model, infection is produced by the application of cell-free virus to abraded skin, where the virus can interact freely with antibodies in serum and tissue fluid. Natural infection is thought to occur when virus contained within the nuclear remnant of desquamated epithelial cells is introduced into abrasions. Therefore, the rabbit model may be more sensitive to the effects of neutralizing antibodies on infection than is transmission of the infection in humans. Nevertheless, CRPV remains a useful animal model for HPV infection.
Materials and Methods
Genes and plasmids. The CRPV DNA for the Ll gene was from plasmid CRPV-pLAII (gift of J. Brandsma, Yale University, New Haven, CT), which contains the entire CRPV genome cloned into pBR322 at the SalI site [17] . The Ll coding sequence was generated by the polymerase chain reaction (PCR), using CRPVpLAII DNA as template. The PCR primers were designed to contain Bam HI sites for cleavage after the PCR fragment was gel purified. The primers used to generate the L1 coding region were (sense) 5' -GGTACAGGATCCACCATGGCAGTGTGGCTGTCT-ACGCAG-3'; (antisense) 5'-CCACATGGATCCTTAAGTACGT-CTCTTGCGTTTAGATG-3' (initiation and stop codons are shown in bold; BamHI sites are underlined).
The L2 coding region also was generated by PCR, but not directly from CRPV-pLAII template. The L2 gene was disrupted at the SalI site when the CRPV genome was inserted into pBR322 to make CRPV-pLAII. Therefore, a template for PCR was generated by cutting CRPV-pLAII with SalI, gel purifying the CRPV DNA, and ligating it. The ligated CRPV DNA was used directly as a template for PCR. The PCR primers were designed to contain BamHI sites for cleavage after the PCR fragment was gel purified. The primers used to generate the L2 coding region were (sense) 5' -GGTACAGGATCCACCATGGTTGCACGGTCACGAAAA-CGC-3'; (antisense) 5'-CCACATGGATCCTTATTCTGCGTA-GACAGCCACACT-3' (initiation and stop codons shown in bold; BamHI sites are underlined). The PCR fragments were gel purified, cut with BamHI, and ligated to VlJns cut with BglII, as previously described [18] with minor modifications. The vector VlJns was derived from the vector VlJ [18] by replacement of the ampicillinresistance gene with a kanamycin-neomycin-resistance gene. The expression vectors VlJ [18] and VlJns contain the cytomegalovirus EIA enhancer, promoter, and intron A (CMVintA) for transcription initiation and the bovine growth hormone (BGH) terminator for transcription termination and polyadenylation in a pUC 19 backbone. The entire lac operon was removed from pUCI9 and replaced with a fragment containing the CMVintA/BGH sequence [18] . All genes were inserted into the BglII site between CMVintA and BGH.
CRPV model. Five rabbits per group were injected intramuscularly with 1 mg of VlJns-Ll or VlJns-L2, a mixture of 1 mg each of VlJns-Ll and VlJns-L2, or with 1 mg of VlJns (the immunization vector lacking the antigen gene). The DNA dose was chosen arbitrarily. Three weeks after the initial DNA injection, rabbits received a second injection ofthe same DNA. The immunizations were given in a total volume of 1.8 mL that was distributed equally (0.3 mL/site) among six intramuscular sites, bilaterally in the rectus femoris, triceps brachialis, and paraspinous muscles. (In subsequent studies, two 60-JLg immunizations [6 sites as above] of Ll DNA were found to be sufficient to induce ELISA titers that were comparable to those in the rabbits given higher doses [600 JLg/immunization] of DNA [P = .15 by t test 12 weeks after the initial immunization]). Four weeks after the second I-mg injection, the rabbits were challenged with CRPV.
CRPV stock virus (obtained from J. Kreider, Pennsylvania State University School of Medicine, Hershey) was prepared using cottontail rabbit skin fragments infected with CRPV and implanted under the renal capsules of athymic mice. The resulting papillomas were homogenized and clarified by centrifugation. The CRPV challenge was done by applying 50 JLL of two dilutions of virus stock (diluted 1:2 or 1:12 with Dulbecco's modified Eagle medium [DMEM] plus 1% bovine serum albumin [BSA]) to triplicate 1-cnr' sites of shaved, scarified skin on the back of each anesthetized rabbit. The dilutions were applied on separate sets of triplicate sites. The animals were observed for formation of papillomas at 3,6, and 10 weeks after challenge. Animals with papillomas were euthanized 10 weeks after infection; animals without papillomas were observed for 6 months after infection.
Transfer of immune serum. Serum donor rabbits were hyperimmunized with Ll DNA by administration of 4 I-mg injections; the dose was selected arbitrarily as above. Peripheral blood was Residual epithelial scarring is present due to scarification, but no papillomas are present in rabbit given L1 DNA. Challenge sites on immunized rabbits that were negative at 6 weeks had no evidence of papillomas 6 months after challenge. collected weekly beginning 10 weeks after the initial immunization. High-titer sera from 6 rabbits were selected on the basis of ELISA activity and pooled; 250 mL of pooled immune serum was diluted to a total volume of I L with PBS, pH 7.4, and sterilefiltered. Then, each of 5 rabbits was given 200 mL of diluted immune serum that was infused intraperitoneally under ketaminexylazine anesthesia at 10 mL/min. Five control rabbits received normal rabbit serum, similarly diluted. All 10 rabbits were challenged with CRPV 18-24 h after the injection of serum; three sites on each rabbit received a 1:2 dilution of virus stock, and four sites received a 1:12 dilution of virus.
ELISAs. Polystyrene ELISA plates were coated overnight at 4°C with 0.5 ;.tg/well baculovirus-expressed [14] and CsCI gradient-enriched recombinant CRPV Ll VLPs in a 100-;.tL volume. Diluted sera were added and incubated for I h at room temperature. The plates were washed, horseradish peroxidase-labeled goat antirabbit IgG (Fe) was added, and the plates were incubated for 1 h. The plates were then washed, and substrate was added. Plates were read at 450 run using a kinetic ELISA reader (Molecular Devices, Menlo Park, CA). Preimmune sera had no ELISA activity. Titers were determined by interpolation of the resulting curve of reaction rate versus dilution to a rate of 10 mOD/min.
Virus neutralization assays. Sera were tested for virus-neutralizing antibody as described by Lin et al. [12] with minor modifications. Equal volumes of IO-fold serial dilutions of immune serum were mixed with a 1:3 dilution ofCRPV stock virus (Kreider strain). Dilutions were prepared in DMEM (GIBCO, Grand Island, NY) supplemented with 1% (wt/vol) BSA (Pierce, Chicago). For virus neutralization assays, the mixtures of immune serum and virus stock were incubated on ice for~60 min, then 50 ;.tL of each mixture was applied to a l-crrr' area of shaved, scarified skin on the backs of 3 New Zealand White rabbits anesthetized with ketamine (12 mg/kg; Fort Dodge Laboratories, Fort Dodge, IA) and xylazine (2.5 mg/kg; Miles Agricultural Division, Shawnee Mission, KS). We observed the animals for 7 weeks for the presence of papillomas and recorded anteroposterior and lateral dimensions (in millimeters) ofthe ellipsoidal papillomas. End-point titers were determined by Reed-Muench interpolation from the frequency of papillomas produced by the various dilutions to an end point of 50% inhibition of wart formation. The statistical comparison of ELISA versus neutralization titers was done by concordance analysis of log-transformed data [19] .
Absorption of immune sera. Nitrocellulose membranes (Hybond; Amersham, Arlington Heights, IL) were coated with 100 J-lg of protein/em" of CRPV VLP of~75% purity expressed in Saccharomyces cerevisiae [16] in native particulate form or denatured by reduction and alkylation in 8 M urea. Membranes were blocked overnight at 4°C in TTBS (TRIS-buffered saline, pH 7.4, with 0.05% Tween-20) with 10% nonfat dry milk and then washed with TTBS. Immune rabbit sera were diluted I: I0 and incubated three successive times (8 h each) with fresh antigen-coated nitrocellulose at 4°C with mixing. The absorbed serum was then assayed for ELISA and virus neutralizing activity. ELISAs were done as described above. Preimmune sera had no ELISA activity.
Results
Rabbits that had been immunized with 11 DNA or with control vector were challenged with stock infectious CRPV at two dilutions: 1:2 (sufficient to infect 100% of sites challenged) or 1:12 (sufficient to infect 80%-95% of sites challenged). Table I shows that all rabbits immunized with 11 DNA alone were resistant to the induction of papillomas by CRPV challenge, whereas all control animals developed papillomas at sites challenged with either dilution of virus stock. Rabbits that had been immunized with L2 DNA developed papillomas with a frequency similar to that of controls. When rabbits were immunized with a mixture of 11 and L2 DNA, 4 of 5 animals immunized were completely protected 6 weeks after challenge. One of the 5 animals given a mixture of 11 and L2 DNA grew a single small papilloma by 6 weeks after challenge, while the other five sites on the same animal remained negative. Papillomas appeared on control rabbits within 6 weeks after challenge (figure I top). Rabbits that had been immunized with 11 or mixed 11 and L2 DNA and did not develop papillomas (figure I bottom) were observed for 6 months after challenge; no new papillomas were seen. Figure 2A shows that sera from rabbits injected intramuscularly with a single immunization of L 1 DNA contained antibodies detectable by ELISA when 11 VLPs prepared in a baculovirus expression system were used as antigen. ELISA titers in rabbits persisted undiminished for at least 32 weeks after immunization. Antibodies that were induced by L 1 DNA immunization neutralized infectious CRPV when virus stock was mixed with the immune serum and applied to scarified skin. Comparison of ELISA and neutralization titers of individual sera revealed a logarithmic relationship ( figure 2B ). This suggests there is a good correlation between activity in the anti-VLP ELISA and neutralizing antibody titers. Furthermore, intraperitoneal injection of pooled immune serum (from rabbits that had been immunized with 11 DNA) into naive rabbits before challenge with CRPV protected them from developing papillomas (table 2). Only I papilloma was observed in 35 sites challenged on rabbits given immune serum, whereas 32 papillomas occurred at 37 sites on rabbits given normal serum. Thus, the antibody response induced by the 11 DNA immunization was sufficient to mediate protection against virus-induced papillomas.
We did absorption experiments to determine if the protective neutralizing antibodies recognized conformational epitopes on VLPs. Absorption of immune serum with 11 VLP removed all of the neutralizing antibody and ELISA activity (figure 3). The application to scarified skin of CRPV mixed with preimmune rabbit serum resulted in papillomas on all sites challenged; however, when CRPV was mixed with immune serum and similarly applied, no papillomas were seen (due to the neu- ... tralizing antibody activity). When CRPV was mixed with immune serum that had been absorbed with L I VLPs, from which the neutralizing antibodies should have been removed, all three sites were positive for papillomas. In contrast, when immune serum was absorbed with denatured, nonparticulate L1 protein (denatured by reduction and alkylation in 8 Murea), the serum could still neutralize CRPV (figure 3 left) and retained its activity in the ELISA ( figure 3 right) . Thus, the virus-neutralizing antibodies induced by L1 DNA immunization could be removed only by L1 VLPs in a native conformation and not by denatured Ll. The ELISA appears to detect primarily conformationally specific antibodies that react with intact L1 VLP, since the depletion of ELISA activity by absorption corresponded to the removal of neutralizing antibodies (figure 3 right).
Discussion
These results indicate that immunization of rabbits with DNA coding for the L1 protein of CRPV protected the rabbits from developing papillomas upon challenge with infectious CRPV and also induced conformationally specific neutralizing antibodies. When injected in saline directly into tissues ofliving animals, plasmid DNA encoding reporter genes gave maximum reporter gene expression in skeletal muscle cells, relative to DNA injected into other tissues, such as liver, brain, endothelium, and epithelium [20] [21] [22] [23] . It is thought that mature myocytes take up the injected plasmid DNA, resulting in the delivery of plasmid DNA to the nuclei of mature myotubes [24] . Once in the nuclei of transfected myotubes, the DNA plasmids appear to remain as closed circles [25, 26] . Published studies to date have not disclosed evidence of integration of the injected plasmid DNA into the myocyte genome [25, 26] . In the case of reporter genes, such as luciferase, expression of the protein encoded by the plasmid DNA reaches a maximum and then decreases for 6-10 weeks after injection; however, it can be maintained at detectable levels for > 1 year [25] . Expression of hepatitis B surface antigen, as detected by immunohistochemistry, appears to persist only several weeks [27] .
Viral proteins produced by the transfected myotubes may be released from the cells, even when the proteins lack secretion signal sequences and contain nuclear localization signals. For example, although influenza nucleoprotein (NP) contains nuclear localization signals and lacks a secretion signal sequence, muscle cells transiently transfected with NP DNA secrete as much as half of their NP into the supernatant (unpublished data), and when NP DNA is injected into mice, high titers of anti-NP antibodies are induced [7] . Intramuscular injection of NP DNA also elicits strong major histocompatibility complex class I-restricted CTL responses [7] , in contrast to the intramuscular injection of purified NP protein, which in our studies induced high titers of antibody but no detectable CTL [28] . The immunologic mechanisms by which NP expressed in muscle cells elicits primary CTL responses remain to be determined.
The HA of influenza virus is an integral membrane protein that is targeted for expression on the surface of infected cells, and injection ofHA DNA elicits HI and neutralizing antibodies [7, 8] . Since the epitopes of influenza HA that are recognized by HI antibodies are conformational in nature and in some instances are formed only by fully mature homotrimers, the ability of DNA immunization to elicit such antibodies suggests that the appropriate conformation of the encoded protein was produced.
In the present studies, CRPV L1 DNA induced virus-neutralizing antibodies capable of recognizing mature CRPV virions and VLPs. Spontaneous association of L1 into capsomers and mature VLPs has been reported in vaccinia virus expression systems and in insect cells and yeast [4, 5, 16, 16a] . Immunization of rabbits with CRPV L1 expressed in Escherichia coli as a trpE fusion protein also induced a protective immune reponse, provided that the protein was not denatured [6] . Thus, the assembly of CRPV L1 into capsomers or VLP may occur in a wide variety of environments; in skeletal muscle cells transfected in vivo, the site of association of L1 monomers into higher-order structures remains to be determined.
Vaccination with DNA offers a number of potential advantages over certain conventional inactivated virus and subunit vaccines. First, DNA immunization shares with recombinant and subunit approaches the ability to use viral gene sequences derived by PCR directly from human clinical specimens of virus-infected tissue. To date it has been possible to propagate only one type of HPV (HPV-ll) in tissue culture [29] [30] [31] [32] ; therefore, inactivated and attenuated live vaccines are not technically feasible.
Second, delivery of a combination of capsid proteins as plasmid DNAs would simplify the preparation of a multivalent HPV vaccine, since the purification and characterization of only a single chemical entity (DNA), rather than many individual proteins, would be required. Studies of DNA vaccines prepared using genes from influenza A virus have shown that multiple plasmids can be combined into a single inoculum to yield an effective multivalent vaccine. Moreover, in some instances, Number of Absorptions Figure 3 . Effect of absorption with cottontail rabbit papillomavirus L1 virus-like particles (VLPs) on antiserum obtained by immunization with L1 DNA. Left, normal and immune sera absorbed with native or denatured VLPs (as in [15] ) were tested for virus neutralizing activity. Mean areas of papillomas are shown at 3 sites 7 weeks after challenge. Right, immune serum from rabbit injected with LI DNA and serially absorbed 3 times with native (.) or denatured (.) LI VLP expressed in recombinant Saccharomyces cerevisiae strain. After each serial absorption, ELISAs were done on serum aliquots to detect antibody activity against recombinant baculovirus-derived L1 VLP. ELISA titer of absorbed material is plotted as % of original ELISA titer of unabsorbed serum.
combining plasmids may increase the efficacy of the DNA vaccine [8] . The present studies indicate that the Ll protein produced by DNA injection bears epitopes capable of inducing neutralizing antibodies. Demonstration of the integrity of the coding region of the plasmid DNA between lots of a DNA vaccine can be accomplished with current technology. Third, intramuscular injection of DNA may provide a sustained production of protein [25] that may result in increased duration of protective immunity, as shown in the present study in which antibody titers persisted essentially unchanged for 32 weeks. Finally, immunization with DNA is an effective means of inducing cellular immunity [7] . Studies in mouse models using other methods of immunization have indicated that potentially cross-protective CTL responses can be made against conserved sequences of early proteins of HPV [33] [34] [35] . Early proteins of HPV regulate viral gene expression and can act as transforming oncogenes. Therefore, immune responses against these proteins may provide cross-strain protection against incipient carcinomas and against condylomas [33] [34] [35] . Immunization with purified protein and subunit vaccines is not generally considered to be an efficient means of inducing CTL responses [36] .
The results ofthe present studies suggest that a DNA vaccine merits consideration as a potential alternative or supplement to other approaches for the vaccination of humans against HPV.
